Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug targets Hard-to-Treat brain metastases

NCT ID NCT05865990

Completed Disease control Sponsor: MedSIR Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a drug called patritumab deruxtecan (HER3-DXd) in 63 patients with breast cancer, lung cancer, or other solid tumors that had spread to the brain or the lining of the brain and spinal cord. The drug is designed to seek out and destroy cancer cells carrying the HER3 protein. The main goals were to see if the drug could shrink brain tumors and improve survival at 3 months. Patients received the drug every 3 weeks until their disease worsened or side effects became too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Patritumab deruxtecan (HER3-DXd), a drug that targets HER3 and delivers chemotherapy to cancer cells
What this could lead to
If it works, this could offer a new treatment option for cancers that have spread to the brain or spinal lining, where options are limited.
What could go wrong
This is a small, early-phase trial with no control group, so results may not be definitive. The drug can cause side effects like nausea, fatigue, and lung inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer breast cancer breast carcinoma breast neoplasm Meningeal Neoplasms neoplastic meningitis non-small cell lung carcinoma non-small cell squamous lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED NON-SMALL CELL SQUAMOUS LUNG CANCER METASTATIC BREAST CANCER SOLID TUMOR, ADULT

Contacts and locations

Locations

  • Hospital Arnau de Vilanova de Valencia

    Valencia, Spain

  • Hospital Beata María Ana

    Madrid, Spain

  • Hospital Quirónsalud Sagrado Corazón

    Seville, Spain

  • Hospital Universitari Dexeus

    Barcelona, Spain

  • Hospital Universitari Vall D'Hebron

    Barcelona, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Spain

  • Medical University of Vienna

    Vienna, Austria

  • Salzburg Cancer research Institute-Center for Clinical Cancer and Immunology Trials

    Salzburg, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.